Can a diabetes drug protect the heart after a massive attack?
NCT ID NCT06174753
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether dapagliflozin, a diabetes drug, can limit heart muscle damage in people having a major heart attack (STEMI). Participants receive either the drug or a placebo for 7 days, and heart damage is measured with an MRI. The goal is to see if this drug can improve recovery and reduce future heart problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug that may protect the heart)
What this could lead to
If it works, this could show that dapagliflozin reduces heart muscle damage after a heart attack, potentially improving recovery and lowering future heart risks.
What could go wrong
This is a relatively small phase 3 trial (256 people) focused on a specific type of heart attack. The drug may not reduce damage as hoped, and side effects like dehydration or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y 4W7, Canada
Contact